Physician profile
Ann MD Abrameit
NPI 1407229693
$1,096.16
in general payments reported to CMS, 2019-2025
15 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.47 · 2021: $108 · 2022: $19.23 · 2023: $415 · 2024: $213 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.23 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $377.77 | 2023-2025 | Veozah |
| Pfizer INC. | $136.98 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2023 | Andexxa |
| Acacia Pharma INC | $108.24 | 2021 | |
| Exact Sciences Corporation | $100.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $51.35 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lundbeck LLC | $32.03 | 2025 | Rexulti |
| Lilly USA, LLC | $30.19 | 2024-2025 | Mounjaro, Zepbound |
| Mayne Pharma Commercial LLC | $28.55 | 2023 | |
| Optinose US, INC. | $22.68 | 2024 | |
| Glaxosmithkline, LLC. | $19.23 | 2022 | |
| Dynavax Technologies Corporation | $18.06 | 2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $16.77 | 2025 | Voquezna |
| Tolmar, INC. | $16.40 | 2025 | Jatenzo |
| Merck Sharp & Dohme LLC | $12.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Abrameit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.